Evidence map›Paper›PMID 40062409›Full record

SynthesisJournal of the European Academy of Dermatology and Venereology : JEADV2026

Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials.

Laura Calabrese, Alessandra Cartocci, Pietro Rubegni, Lars E French, Benjamin Kendziora

Registry-linked trialAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06926192 (Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa), which is not on this map. Cited by 7 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06926192 recruitingnot on this map

Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: An Open-label Cohort Study in Real Clinical Practice

TypeobservationalSponsorPeking Union Medical CollegeRan2020 to 2025Enrolled100ConditionsHidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa), SecukinumabArmsSurgery combined with secukinumab
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Short-term efficacy of biologics in moderate-to-severe hidradenitis suppurativa: A systematic review and NMA.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Pooled it
  2. Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. A tale of two meta-analyses: Similarity, consistency and avoiding overinterpretation in network meta-analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Laura CalabreseDermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.ORCID https://orcid.org/0000-0001-5238-2336
Alessandra CartocciDermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
Pietro RubegniDermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
Lars E FrenchDepartment of Dermatology and Allergy, University Hospital, LMU, Munich, Germany.ORCID https://orcid.org/0000-0002-4629-1486
Benjamin KendzioraDepartment of Dermatology and Allergy, University Hospital, LMU, Munich, Germany.ORCID https://orcid.org/0000-0002-5234-5380

Funding

European Union (EU)-Next Generation European Union Mission 4 Component 2 Inv. 1.5 CUP B63C22000680007Munich Clinician Scientist Program (MCSP) of the Ludwig Maximilian University (LMU) CS 067
6 · The paper itself

Abstract

backgroundPhase III clinical trials are designed to evaluate the therapeutic effect of drugs and their superiority over other treatment methods, but biologics for hidradenitis suppurativa (HS) have not been compared head-to-head in phase III studies.

objectivesTo evaluate the relative efficacy and safety of biologics for HS in a network meta-analysis including available data from phase III trials.

methodsMEDLINE and Embase were searched for phase III trials investigating the efficacy and/or safety of at least one biologic for moderate-to-severe HS. The odds ratios for reaching an HS Clinical Response 50 (HiSCR50) and for the occurrence of adverse events after 12-16 weeks were compared between treatments.

resultsPIONEER I and II (adalimumab 40 mg weekly vs. placebo), SUNSHINE and SUNRISE (secukinumab 300 mg every 2 vs. 4 weeks vs. placebo) as well as BE HEARD I and II (bimekizumab 320 mg every 2 vs. 4 weeks vs. placebo) with 2731 patients were included. Adalimumab weekly was ranked most effective in reaching a HiSCR50 with significant superiority over secukinumab every 2 weeks (OR = 1.74; 95% confidence interval [CI]: 1.11-2.73) and 4 weeks (OR = 1.72; 95% CI: 1.09-2.7) and insignificant superiority over bimekizumab every 2 weeks (OR = 1.23; 95% CI: 0.74-2.06) and 4 weeks (OR = 1.25; 95% CI: 0.73-2.14). Adalimumab showed the fewest adverse events with significant superiority over bimekizumab every 2 weeks (OR = 0.52; 95% CI: 0.32-0.86) and insignificant superiority over bimekizumab every 4 weeks (OR = 0.79; 95% CI: 0.47-1.33) and secukinumab every 2 weeks (OR = 0.69; 95% CI: 0.45-1.07) and 4 weeks (OR = 0.71; 95% CI: 0.46-1.1).

conclusionsAmong currently approved biologic agents for moderate-to-severe HS, adalimumab demonstrated the highest efficacy and safety in the first 12-16 weeks of treatment.

Indexed as

Biological ProductsHidradenitis SuppurativaAdalimumabAntibodies, Monoclonal, HumanizedClinical Trials, Phase III as TopicHumansNetwork Meta-Analysis as TopicTreatment OutcomeAdalimumabAntibodies, Monoclonal, HumanizedbimekizumabBiological Productssecukinumab

Identifiers

PMID40062409
PMCPMC13014433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.